Anaptys has cash, cash equivalents and investments greater than $420M as of December 31, 2024, and anticipates receipt of a $75M commercial ...

AnaptysBio (ANAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

AnaptysBio (NASDAQ:ANAB – Get Free Report) and Silo Pharma (NASDAQ:SILO – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses ...

It's important to note that despite the potential full execution of the stock repurchase plan, AnaptysBio has reiterated its ...

AnaptysBio shares rose 7.2% on a share-repurchase program authorized to buy back up to $75 million of the company's common stock. Shares were recently trading around $18.31. The stock is down 15% over ...

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its ...

Shares of AnaptysBio (NASDAQ: ANAB) climbed 12% today as the company announced a significant stock repurchase plan, signaling confidence in its financial position and future prospects. The ...

Intuitive Machines reported fourth-quarter revenue of $54.66 million, missing analyst estimates of $55.77 million, according ...

SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its ...

Sustainalytics’ controversies research identifies companies involved in incidents and events that may negatively affect stakeholders, the environment or the company’s operations. Controversies are ...

AnaptysBio reported $43.1 million in collaboration revenue ... increase our POS [probability of success] for both ros’ RA and UC programs, and think the stock setup remains good in 2025 as: 1) 28wk ...